Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Mallinckrodt
AstraZeneca
Chinese Patent Office
McKinsey
Fish and Richardson
Queensland Health
Citi
Moodys
QuintilesIMS

Generated: January 21, 2018

DrugPatentWatch Database Preview

Gadofosveset trisodium - Generic Drug Details

« Back to Dashboard

What are the generic sources for gadofosveset trisodium and what is the scope of gadofosveset trisodium freedom to operate?

Gadofosveset trisodium
is the generic ingredient in one branded drug marketed by Lantheus Medcl and is included in one NDA. There is one patent protecting this compound. Additional information is available in the individual branded drug profile pages.

Gadofosveset trisodium has forty-three patent family members in twenty-six countries.

Summary for gadofosveset trisodium
International Patents:43
US Patents:1
Tradenames:1
Applicants:1
NDAs:1
Bulk Api Vendors: 2
Clinical Trials: 18
Formulation / Manufacturing:see details
Drug Prices:see low prices
DailyMed Link:gadofosveset trisodium at DailyMed

US Patents and Regulatory Information for gadofosveset trisodium

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Lantheus Medcl ABLAVAR gadofosveset trisodium SOLUTION;INTRAVENOUS 021711-001 Dec 22, 2008 DISCN No No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Lantheus Medcl ABLAVAR gadofosveset trisodium SOLUTION;INTRAVENOUS 021711-002 Dec 22, 2008 DISCN No No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Expired US Patents for gadofosveset trisodium

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Lantheus Medcl ABLAVAR gadofosveset trisodium SOLUTION;INTRAVENOUS 021711-001 Dec 22, 2008 ➤ Subscribe ➤ Subscribe
Lantheus Medcl ABLAVAR gadofosveset trisodium SOLUTION;INTRAVENOUS 021711-002 Dec 22, 2008 ➤ Subscribe ➤ Subscribe
Lantheus Medcl ABLAVAR gadofosveset trisodium SOLUTION;INTRAVENOUS 021711-001 Dec 22, 2008 ➤ Subscribe ➤ Subscribe
Lantheus Medcl ABLAVAR gadofosveset trisodium SOLUTION;INTRAVENOUS 021711-002 Dec 22, 2008 ➤ Subscribe ➤ Subscribe
Lantheus Medcl ABLAVAR gadofosveset trisodium SOLUTION;INTRAVENOUS 021711-002 Dec 22, 2008 ➤ Subscribe ➤ Subscribe
Lantheus Medcl ABLAVAR gadofosveset trisodium SOLUTION;INTRAVENOUS 021711-001 Dec 22, 2008 ➤ Subscribe ➤ Subscribe
Lantheus Medcl ABLAVAR gadofosveset trisodium SOLUTION;INTRAVENOUS 021711-001 Dec 22, 2008 ➤ Subscribe ➤ Subscribe
Lantheus Medcl ABLAVAR gadofosveset trisodium SOLUTION;INTRAVENOUS 021711-001 Dec 22, 2008 ➤ Subscribe ➤ Subscribe
Lantheus Medcl ABLAVAR gadofosveset trisodium SOLUTION;INTRAVENOUS 021711-001 Dec 22, 2008 ➤ Subscribe ➤ Subscribe
Lantheus Medcl ABLAVAR gadofosveset trisodium SOLUTION;INTRAVENOUS 021711-002 Dec 22, 2008 ➤ Subscribe ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents for gadofosveset trisodium

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,394,356 Diagnostic imaging contrast agents with extended blood retention ➤ Subscribe
7,011,815 Diagnostic imaging contrast agents with extended blood retention ➤ Subscribe
7,060,250 Diagnostic imaging contrast agents with extended blood retention ➤ Subscribe
8,017,105 Diagnostic imaging contrast agents with extended blood retention ➤ Subscribe
7,229,606 Diagnostic imaging contrast agents with extended blood retention ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents for gadofosveset trisodium

Supplementary Protection Certificates for gadofosveset trisodium

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0253 Netherlands ➤ Subscribe 300253, 20160116, EXPIRES: 20201002
C0028 France ➤ Subscribe PRODUCT NAME: GADOFOSVESET TRISODIQUE; REGISTRATION NO/DATE: EU/1/05/313/001-009 20051003
C 037/2006 Ireland ➤ Subscribe SPC 037/2006: 20070528, EXPIRES: 20201002
2007003 Lithuania ➤ Subscribe PRODUCT NAME: GADOFOSVESETUM TRINATRICUM; REG NO/DATE: EU/1/05/313/001-009 20051005
2007003,C0806968 Lithuania ➤ Subscribe PRODUCT NAME: GADOFOSVESETUM TRINATRICUM; REGISTRATION NO/DATE: EU/1/05/313/001, 2005 10 05 EU/1/05/313/002, 2005 10 05 EU/1/05/313/003, 2005 10 05 EU/1/05/313/004, 2005 10 05 EU/1/05/313/005, 2005 10 05 EU/1/05/313/006, 2006 10 05 EU/1/05/313/007, 2005 10 05 EU/1/05/313/008, 2005 10 05 EU/1/05/313/00 2005100
2007 00016 Denmark ➤ Subscribe
C/GB07/011 United Kingdom ➤ Subscribe PRODUCT NAME: GADOFOSVESET TRISODIUM; REGISTERED: UK EU/1/05/313/001 20051003; UK EU/1/05/313/002 20051003; UK EU/1/05/313/003 20051003; UK EU/1/05/313/004 20051003; UK EU/1/05/313/005 20051003; UK EU/1/05/313/006 20051003; UK EU/1/05/313/007 20051003; UK EU/1/05/313/008 20051003; UK EU/1/05/313/009 20051003
0806968/01 Switzerland ➤ Subscribe FORMER REPRESENTANTIVE: BOVARD AG PATENTANWAELTE, CH
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Julphar
AstraZeneca
Fuji
Novartis
QuintilesIMS
Healthtrust
Chinese Patent Office
Cipla
US Department of Justice

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot